Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

36 results about "Velpatasvir" patented technology

Velpatasvir is an NS5A inhibitor (by Gilead) which is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.

Velpatasvir as well as intermediate and preparation method thereof

The invention discloses velpatasvir as well as an intermediate and a preparation method thereof. The preparation method of velpatasvir 1 provided by the invention comprises the following steps that inan organic solvent, under the condition of existence of alkali, catalysts and condensating agents, a compound 3 and MOC-L-valine take condensation reaction to obtain velpatasvir 1. The preparation method has the advantages that the reaction conditions are mild; the operation is simple and safe; specific purification equipment is not needed; the column chromatography separation operation in the aftertreatment process is avoided; the chiral isomer is easy to control; the yield is high; the chemical and optical purity of the prepared velpatasvir is greater than 99.50 percent; all impurities aresmaller than 0.10 percent; the raw material medicine standard can be reached; the cost is low; the preparation method is suitable for industrial production. The formula is shown in the description.
Owner:上海云晟研新生物科技有限公司

Velpatasvir intermediate as well as preparation method and application thereof

The invention discloses a velpatasvir intermediate as well as a preparation method and application thereof. The preparation method of a velpatasvir intermediate compound 4 provided by the invention comprises the following steps that under the protection of protection gas, in the organic solvent, a compound 5 and an oxidizing agent take oxidation reaction to obtain a compound 4. The velpatasvir isprepared from the intermediate compound 4; the reaction conditions are mild; the operation is simple and safe; specific purification equipment is not needed; the column chromatography separation operation in the aftertreatment process is avoided; the chiral isomer is easy to control; the yield is high; the chemical and optical purity of the velpatasvir prepared from the intermediate compound 4 isgreater than 99.50 percent; all impurities are smaller than 0.10 percent; the raw material medicine standard can be reached; the cost is low; the preparation method is suitable for industrial production. The formula is shown in the description.
Owner:上海云晟研新生物科技有限公司

Preparation method of velpatasvir intermediate and analogue thereof

The invention discloses a preparation method of a compound shown by formula (E), a velpatasvir intermediate shown by formula (K) and an analogue thereof. Materials adopted in the method disclosed by the invention are low-cost and easily obtained; the technological operation is simple; the intermediate and the product need not be subject to column chromatography separation; and the preparation method is suitable for industrialized mass production.
Owner:XILING LAB CO LTD

Preparation method of benzochromene derivative

The invention discloses a preparation method of a benzochromene derivative shown as a formula (I). The benzochromene derivative can be taken as a synthesis intermediate of a drug such as a synthesis intermediate of Velpatasvir. Cheap and available 2-fluoro halogenated benzene is taken as a starting material, a brand-new synthetic route for preparing the benzochromene derivative is provided, the total yield of the whole reaction route is high, and the method is suitable for large-scale industrial production.
Owner:ASTATECH CHENGDU BIOPHARM CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products